Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company`s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.
Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point-of-care testing and third generation sequencing.
PacketDNA Inc. is a Kanata, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
20/20 GeneSystems Inc is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vium is the first company to create a living informatics platform for preclinical in vivo drug research.